Sei Investments Co. Grows Position in Repligen Corporation $RGEN

Sei Investments Co. grew its stake in shares of Repligen Corporation (NASDAQ:RGEN) by 49.5% in the first quarter, HoldingsChannel.com reports. The firm owned 272,103 shares of the biotechnology company’s stock after buying an additional 90,115 shares during the quarter. Sei Investments Co.’s holdings in Repligen were worth $32,061,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in RGEN. Massachusetts Financial Services Co. MA bought a new stake in Repligen in the 4th quarter worth $199,176,000. M&T Bank Corp bought a new position in shares of Repligen during the fourth quarter valued at about $29,819,000. Swedbank AB bought a new position in shares of Repligen during the fourth quarter valued at about $4,146,000. Conestoga Capital Advisors LLC boosted its holdings in shares of Repligen by 10.6% during the fourth quarter. Conestoga Capital Advisors LLC now owns 1,057,975 shares of the biotechnology company’s stock worth $173,360,000 after purchasing an additional 101,062 shares during the period. Finally, Jennison Associates LLC purchased a new stake in shares of Repligen during the fourth quarter worth about $20,253,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. Barclays boosted their price target on Repligen from $145.00 to $160.00 and gave the company an “overweight” rating in a report on Wednesday, May 6th. Benchmark upgraded Repligen from a “hold” rating to a “buy” rating and set a $185.00 price objective for the company in a report on Tuesday, July 7th. Weiss Ratings upgraded Repligen from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, July 14th. Evercore reissued an “outperform” rating and set a $160.00 target price on shares of Repligen in a research note on Monday, July 6th. Finally, Wolfe Research began coverage on Repligen in a report on Tuesday, June 2nd. They set an “outperform” rating and a $145.00 target price for the company. Two research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $165.36.

Insider Activity

In other news, CFO Jason K. Garland sold 733 shares of the stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $145.00, for a total value of $106,285.00. Following the completion of the transaction, the chief financial officer owned 19,359 shares of the company’s stock, valued at approximately $2,807,055. This represents a 3.65% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.60% of the company’s stock.

Repligen Price Performance

Shares of NASDAQ RGEN opened at $131.06 on Tuesday. Repligen Corporation has a 1 year low of $100.99 and a 1 year high of $175.77. The company has a debt-to-equity ratio of 0.26, a current ratio of 9.20 and a quick ratio of 7.78. The company’s 50-day moving average is $132.21 and its 200 day moving average is $132.05. The stock has a market capitalization of $7.39 billion, a P/E ratio of 145.62, a P/E/G ratio of 2.54 and a beta of 1.06.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.38 by $0.10. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The company had revenue of $194.25 million during the quarter, compared to the consensus estimate of $192.05 million. During the same period in the prior year, the firm earned $0.39 earnings per share. Repligen’s revenue was up 14.8% on a year-over-year basis. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. On average, sell-side analysts expect that Repligen Corporation will post 1.99 earnings per share for the current year.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.